Impact of Our Study

Why do we need this consortium?

  • This consortium aims to focus on rarity of this disease and it’s need for investigators to come together for a cohesive structured systematic approach
  • International nature makes it widely applicable and generalizable and captures clinical, demographic, socio economic, geographic heterogeneity which is critical for universalizing care and treatment for patients

Urgent Need for Genomics Information

We are a global coordinated team of clinical experts and researchers performing genomics and utilizing deep learning tools to correlate with clinical data in a prospective longitudinal study.

  • There are no large scale longitudinal genomic studies in T-cell lymphomas to understand refractoriness and relapse. This initiative is desperately needed.
  • Genomics via Next generation sequencing (NGS) enables the characterization of the somatic and germline defects in individual tumor samples which is needed for identifying therapeutic options.
  • Genomics can reveal personalized targetable aberrations, mutational burden, complex molecular signatures, tumor-specific antigens which will inform utilization of diverse therapies from targeted drugs, epigenetic modifiers, small molecule inhibitors and cellular therapies.
  • The occurrence of common alterations across diverse T-cell lymphoma types will prompt new paradigms in the application of genomic profiling and the design of clinical trials.

Need for Machine Learning

  • With the increasing number of complex Next Generation Sequencing datasets, we need artificial intelligence/machine learning-based computational tools that can handle, extract, and interpret the valuable information hidden within this large aggregation of data.
  • Typically, large amounts of stereotypical clinical data are needed for estimating high precision individual outcomes. Cutting edge machine learning methodologies like synthetic intervention can make accurate outcomes with reduced data and attributes.